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But if with this tenn we state that any stenotic vessel has to be 
grafted, regardless of its importance and size, without any 
demonstration of ischemia in the territory, this definition of 
"complete revascularization" has to be forgotten. Today we 
have at our disposition many tools to properly investigate the 
importance of a stenosis, and complete revascularization 
(interventional, surgical, or combined) of all ischemic territo-
ries is always our goal. However, the timing can change and 
the strategy can differ from patient to patient. 
In our article I thought that the real problem was focused 
not on the surgical indication (single LAD disease or multi-
ple-vessel disease), which can be debatable, but on the future 
of the graft. (Is this approach able to guarantee satisfying per-
meability of the graft? Can this strategy be considered safe 
and reproducible?) For this reason I mixed all my patients, but 
the patients with "multiple-vessel disease" in this group, with 
only a few exceptions (hybrid procedures), are not the same 
patients we operate on every day in our daily practice. 
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The use of the calcium antagonist nicardipine in 
arterial coronary bypass surgery 
To the Editor: 
In the December 1998 issue of the Journal, Acar, l Possati,2 
and their associates independently provided important data on 
the 5-year patency rate of the radial artery graft. 
Both groups acknowledge the impressive spastic character-
istics of this arterial conduit and advocate peri operative 
release of spasm and routine administration of the calcium 
antagonist diltiazem to the patients for 1 year or more. 
Interruption of this treatment after 1 year or later during fol-
low-up did not seem to adversely influence either clinical out-
come or 5-year patency. This observation is related to the 
apparent loss of reactivity of the radial graft over time. 
The use of antispasmodic drugs for patients receiving arte-
rial grafts is a common practice, although so far no study has 
demonstrated its value on the surgical outcome, keeping in 
mind that "spasm" may be confounded by other factors such 
as surgical technique, familiarity with arterial grafts, and peri-
operative conduit preparation. Since 1994, we have been 
using nicardipine hydrochloride, the first intravenously 
administered dihydropyridine calcium channel antagonist, for 
sequential or bilateral internal thoracic artery grafting. The 
patients are started perioperatively on intravenous nicardipine 
hydrochloride (0.25 Ilg/kg per minute) after a 1 mg intra-
venous bolus. The drug is titrated according to the systemic 
vascular resistance and discontinued on the second postoper-
ative day. For patients receiving a radial artery graft, we added 
to this protocol gentle hydrostatic dilatation of the conduit 
with 1 % papaverine and oral administration of nicardipine 20 
to 30 mg three times a day after discontinuation of intra-
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venous perfusion on day 2. The first 50 patients undergoing 
myocardial revascularization with a radial graft using that 
protocol were observed. A total of 150 anastomoses were per-
fonned with a mean of 3.0 anastomoses per patient, and 108 
arterial grafts were used for the completion of 111 coronary 
distal anastomoses. Fifty radial arteries were used for 52 dis-
tal anastomoses, and 36 venous grafts were used for 39 distal 
anastomoses. The radial artery was placed on the obtuse mar-
ginal branch in 58% of cases, diagonal branches in 13%, and 
the right coronary artery in 29%. Proximal anastomoses were 
done directly on the aorta in 80% of cases. 
The operative mortality was 4% because of 2 cases of ful-
minant pulmonary sepsis. There was no evidence of perioper-
ative myocardial infarction or arterial graft hypoperfusion 
syndrome. Mean creatine kinase MB level at 18 hours was 36 
IlgIL. Neither ischemic anomalies of the electrocardiogram 
nor wall motion abnonnalities on discharge transthoracic 
echocardiography were detected. Angiography perfonned in 
the last 20 patients showed a 98% (51/52) penneability rate 
for all grafts. Nineteen of 20 radial grafts were patent. A mod-
erate spasm (40%) developed in the middle part of the conduit 
in one radial artery. 
Our experience with the radial artery is part of a larger 
experience with the perioperative use of nicardipine in more 
than 550 cases of bilateral or sequential internal thoracic 
artery grafting. This protocol has virtually eliminated internal 
thoracic artery spasm or hypoperfusion in our practice. 
Nicardipine has several potential advantages over diltiazem. 
Nicardipine is a more potent and selective arteriolar vasodila-
tory agent, which also has the capability to inhibit endothelin-
induced vasoconstriction.3 This drug has neither chronotrop-
ic, dromotropic, nor inotropic negative effects. Its short action 
duration makes it convenient for perioperative management, 
and it is well tolerated in association with ~ blockers in the 
routine management of patients with coronary artery disease. 
Nicardipine also has a documented cardioprotective effect on 
ischemic myocardium, and some data suggest cardioprotec-
tive effects during cardioplegic cardiac arrest.4 We therefore 
suggest that the time has come to assess the real need for anti-
spasmodic drugs in arterial coronary bypass grafting and to 
determine the most adequate pharmacologic management for 
patients receiving arterial grafts such as the radial artery. 
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Regional cerebral blood flow and regional glucose 
use during rewarming after hypothermic cardiopul-
monary bypass 
To the Editor: 
We read with great interest the article titled "Regional 
Cerebral Blood Flow During Rewarming of Cardiopulmonary 
Bypass Correlates With Posthypothermic Regional Glucose 
Use" (J Thorac Cardiovasc Surg 1998;116:503-10). The 
authors are to be congratulated on the timely demonstration of 
the potentially deleterious derangements caused by a period 
of hypothermic perfusion followed by rewarming. 
Because cerebral blood flow and metabolism remained cou-
pled during hypothermic (20°C) perfusjon for 60 minutes, but 
apparently not during or after rewarming, particularly in the 
parietal cortex, rewarming was considered to be the culprit. 
However, the 60-minute period of hypothermic perfusion 
used in their protocol 2 might not have been long enough to 
assess the effects of hypothermia per se, since reducing the 
temperature to only 29.5°C can provide protection for 60 min-
utes of total blood flow cessation in a rabbit model of spinal 
cord ischemia with pH-stat ventilation. l Metabolic derange-
ments may result from inadequate oxygen delivery caused by 
the leftward shift of the oxyhemoglobin curve and alkalosis 
induced by hypothermia. Given the relatively short hypother-
mic period with continuous perfusion, these derangements 
may have been present before rewarming, but may have been 
too subtle even for the sophisticated methods used by the 
authors. Those metabolic derangements could not recover fast 
enough during the rewarming time and indeed were exagger-
ated by the increased metabolic rate. Thus they became appar-
ent only after body temperature was returned to normal. If 
metabolism was impaired and oxygen could not be consumed, 
there was no need for flow; consequently, decreased flows 
were o?served. 
Unfortunately, the authors studied only animals with alpha-
stat strategies for pH management during hypothermia. 
Alpha-stat strategies have been considered as the standard for 
many years to avoid the so-called "luxury perfusion" of pH-
stat management and consequent increased chances of 
microembolization. Such "luxury perfusion" may actually not 
be a "luxury" but a necessary compensatory mechanism for 
the leftward shift of the oxyhemoglobin dissociation curve 
induced by hypothermia. A recent report2 indicated better 
neurologic outcome of pH-stat over alpha-stat strategies for 
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deep hypothermic cardiopulmonary bypass in infants, an 
observation that cou1d have been anticipated and should not 
be surprising. Whether this improved outcome was due to bet-
ter blood flow3 or better oxygen delivery and use is irrelevant. 
However, it is in line with the physiologic principles of the 
remarkable constancy of the expiratory carbon dioxide con-
centration remaining close to that observed in normothermic 
conditions in hibernating animals, regardless of the body tem-
perature, by ventilatory rate adjustment, which is the nature-
provided pH-stat management. This is most obvious in poik-
ilothermic animals, 
The authors have the modern methods to resolve the contro-
versial issue of whether alpha-stat is better than pH-stat man-
agement or vice versa. We believe the neurologic injury coin-
cidental to hypothermic perfusion is the result of the algebraic 
sum of both factors, positive metabolic factors and negative 
microembolization. The relative role of each one is variable for 
each individual depending on various factors-the duration of 
the hypothermic perfusion period, the rate of cooling and 
rewarming, the hemodynamic status before and after car-
diopulmonary bypass, the type of oxygenator, and the lack of 
pulsatility. The metabolic component is maximized by pH-stat 
strategy of the ventilation, which restores oxygen delivery to 
the tissues. However, if the supposedly positive metabolic 
influences of hypothermia are less than ideal because of the 
impaired oxygen delivery caused by alpha-stat management, 
which would be equivalent to hypoxic perfusion, the negative 
influence of microembolization will become relatively more 
significant. If sustained for long enough, it would be detri-
mental by itself, thus resulting in overt neurologic impairment. 
Hemodynamic superiority of pH-stat over alpha-stat strate-
gies in dogs during surface-induced hypothermia was report-
ed years before the term of pH -stat management was coined.3 
It would not be surprising if the reported hypotension during 
the hypothermic state and the flow-metabolism derangements 
would be at least abated, if not completely prevented, provid-
ed that expiratory carbon dioxide concentrations of the oxy-
genator are maintained constant close to 5% to 6%. pH-Stat 
strategies are used by controlling the oxygenlblood flow ratio 
of cardiopulmonary bypass (or gasses, by adding carbon diox-
ide, if necessary), not on1y during cooling but during rewarm-
ing as well. 
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